Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 137.63 Thousand USD | -62.89% |
| 2022 | 370.93 Thousand USD | 210.95% |
| 2021 | 119.29 Thousand USD | -63.45% |
| 2020 | 326.4 Thousand USD | 48.62% |
| 2019 | 219.62 Thousand USD | 503.19% |
| 2018 | 36.41 Thousand USD | -94.98% |
| 2017 | 725.66 Thousand USD | 1304.4% |
| 2016 | 51.67 Thousand USD | -7.43% |
| 2015 | 55.81 Thousand USD | -50.73% |
| 2014 | 113.28 Thousand USD | -56.17% |
| 2013 | 258.43 Thousand USD | -39.68% |
| 2012 | 428.43 Thousand USD | 98.27% |
| 2011 | 216.08 Thousand USD | 167.66% |
| 2010 | 80.73 Thousand USD | 34.99% |
| 2009 | 59.8 Thousand USD | 10934.5% |
| 2008 | 542.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 159 Thousand USD | 23.69% |
| 2024 Q2 | 128.55 Thousand USD | 2.4% |
| 2024 Q1 | 125.54 Thousand USD | -8.79% |
| 2023 Q3 | 189.04 Thousand USD | 32.14% |
| 2023 Q1 | 233.53 Thousand USD | -37.04% |
| 2023 FY | 137.63 Thousand USD | -62.89% |
| 2023 Q4 | 137.63 Thousand USD | -27.19% |
| 2023 Q2 | 143.06 Thousand USD | -38.74% |
| 2022 Q1 | 807.92 Thousand USD | 577.28% |
| 2022 Q2 | 568.22 Thousand USD | -29.67% |
| 2022 Q3 | 448.53 Thousand USD | -21.06% |
| 2022 Q4 | 370.93 Thousand USD | -17.3% |
| 2022 FY | 370.93 Thousand USD | 210.95% |
| 2021 Q3 | 762.24 Thousand USD | -15.89% |
| 2021 FY | 119.29 Thousand USD | -63.45% |
| 2021 Q4 | 119.29 Thousand USD | -84.35% |
| 2021 Q1 | 385.3 Thousand USD | 18.05% |
| 2021 Q2 | 906.29 Thousand USD | 135.22% |
| 2020 Q1 | 43.89 Thousand USD | -80.02% |
| 2020 Q3 | 633.00 USD | -85.09% |
| 2020 FY | 326.4 Thousand USD | 48.62% |
| 2020 Q4 | 326.4 Thousand USD | 51464.45% |
| 2020 Q2 | 4246.00 USD | -90.33% |
| 2019 Q1 | 118.93 Thousand USD | 226.63% |
| 2019 FY | 219.62 Thousand USD | 503.19% |
| 2019 Q2 | 45.27 Thousand USD | -61.93% |
| 2019 Q3 | 33.22 Thousand USD | -26.62% |
| 2019 Q4 | 219.62 Thousand USD | 561.01% |
| 2018 Q2 | 686.2 Thousand USD | -0.79% |
| 2018 Q3 | 2831.00 USD | -99.59% |
| 2018 Q1 | 691.7 Thousand USD | -4.68% |
| 2018 FY | 36.41 Thousand USD | -94.98% |
| 2018 Q4 | 36.41 Thousand USD | 1186.15% |
| 2017 Q2 | 21.56 Thousand USD | -26.21% |
| 2017 FY | 725.66 Thousand USD | 1304.4% |
| 2017 Q3 | 76.76 Thousand USD | 255.97% |
| 2017 Q4 | 725.66 Thousand USD | 845.32% |
| 2017 Q1 | 29.22 Thousand USD | -43.44% |
| 2016 Q2 | 56.57 Thousand USD | 12.71% |
| 2016 FY | 51.67 Thousand USD | -7.43% |
| 2016 Q4 | 51.67 Thousand USD | -36.85% |
| 2016 Q3 | 81.82 Thousand USD | 44.65% |
| 2016 Q1 | 50.19 Thousand USD | -10.08% |
| 2015 Q4 | 55.81 Thousand USD | -42.38% |
| 2015 FY | 55.81 Thousand USD | -50.73% |
| 2015 Q1 | 97.61 Thousand USD | -13.83% |
| 2015 Q2 | 119.13 Thousand USD | 22.05% |
| 2015 Q3 | 96.86 Thousand USD | -18.7% |
| 2014 Q1 | 337.66 Thousand USD | 30.66% |
| 2014 FY | 113.28 Thousand USD | -56.17% |
| 2014 Q4 | 113.28 Thousand USD | -49.39% |
| 2014 Q3 | 223.83 Thousand USD | -9.96% |
| 2014 Q2 | 248.59 Thousand USD | -26.38% |
| 2013 Q4 | 258.43 Thousand USD | 6.66% |
| 2013 FY | 258.43 Thousand USD | -39.68% |
| 2013 Q1 | 198.96 Thousand USD | -53.56% |
| 2013 Q2 | 258.13 Thousand USD | 29.74% |
| 2013 Q3 | 242.29 Thousand USD | -6.14% |
| 2012 Q4 | 428.43 Thousand USD | 119.05% |
| 2012 FY | 428.43 Thousand USD | 98.27% |
| 2012 Q1 | 273.39 Thousand USD | 26.52% |
| 2012 Q2 | 275.8 Thousand USD | 0.88% |
| 2012 Q3 | 195.58 Thousand USD | -29.08% |
| 2011 Q2 | 354.61 Thousand USD | 104.65% |
| 2011 FY | 216.08 Thousand USD | 167.66% |
| 2011 Q3 | 263.71 Thousand USD | -25.63% |
| 2011 Q4 | 216.08 Thousand USD | -18.06% |
| 2011 Q1 | 173.27 Thousand USD | 114.64% |
| 2010 Q3 | 59.87 Thousand USD | 225.45% |
| 2010 Q2 | 18.39 Thousand USD | -69.87% |
| 2010 Q1 | 61.05 Thousand USD | 2.09% |
| 2010 FY | 80.73 Thousand USD | 34.99% |
| 2010 Q4 | 80.73 Thousand USD | 34.83% |
| 2009 FY | 59.8 Thousand USD | 10934.5% |
| 2009 Q2 | 71.01 Thousand USD | 65047.71% |
| 2009 Q3 | 63.53 Thousand USD | -10.53% |
| 2009 Q1 | 109.00 USD | 0.0% |
| 2009 Q4 | 59.8 Thousand USD | -5.86% |
| 2008 FY | 542.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -5858.355% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 92.971% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.696% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 75.071% |
| Rebus Holdings, Inc. | 5000.00 USD | -2652.76% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.894% |
| Qrons Inc. | 420.00 USD | -32670.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 82.14% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.507% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 71.359% |
| Skye Bioscience, Inc. | 11.94 Million USD | 98.847% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.646% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.094% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -80.263% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.872% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 90.389% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -90.2% |
| Mesoblast Limited | 667.9 Million USD | 99.979% |
| Marizyme, Inc. | 22.01 Million USD | 99.375% |
| Genus plc | 1.02 Billion USD | 99.987% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 89.867% |
| Pharming Group N.V. | 462.85 Million USD | 99.97% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 95.846% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 72.419% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 78.048% |
| ContraFect Corporation | 20.67 Million USD | 99.334% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 64.741% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 63.986% |
| IMV Inc. | 31.33 Million USD | 99.561% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 96.68% |
| MultiCell Technologies, Inc. | 126.22 USD | -108946.11% |
| ONE Bio Corp. | 70.08 Million USD | 99.804% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 85.353% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.893% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 68.118% |
| Q BioMed Inc. | 3.51 Million USD | 96.085% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.609% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 47.321% |
| Biomind Labs Inc. | 73.81 Thousand USD | -86.453% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.969% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 90.5% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.541% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 94.988% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 79.98% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 94.713% |
| GB Sciences, Inc. | 103.44 Thousand USD | -33.058% |
| Alpha Cognition Inc. | 2.45 Million USD | 94.387% |
| HST Global, Inc. | 1526.00 USD | -8919.528% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 86.069% |
| Halberd Corporation | 10.13 Thousand USD | -1258.583% |
| Enzolytics Inc. | 361.7 Million USD | 99.962% |
| Agentix Corp. | 261.39 Thousand USD | 47.344% |
| Resverlogix Corp. | 8.11 Million USD | 98.304% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 92.671% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.997% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.711% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 78.482% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -504.179% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.462% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.134% |
| Zenith Capital Corp. | 7410.00 USD | -1757.463% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.996% |
| Ember Therapeutics, Inc. | 184.00 USD | -74703.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 57.23% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 47.339% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 85.168% |
| Kadimastem Ltd | 2.3 Million USD | 94.026% |
| Helix BioMedix, Inc. | 3.02 Million USD | 95.45% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.739% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.055% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -141.073% |
| LadRx Corporation | 2.3 Million USD | 94.036% |
| Cell Source, Inc. | 195.17 Thousand USD | 29.478% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 61.077% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 61.077% |
| NovAccess Global Inc. | 62.24 Thousand USD | -121.112% |
| Affymax, Inc. | 7.44 Million USD | 98.151% |
| Itoco Inc. | 1.4 Million USD | 90.169% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -43.887% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -29.847% |
| Mobile Lads Corp. | 52.00 USD | -264588.462% |
| CytoDyn Inc. | 11.13 Million USD | 98.764% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 3.731% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -669.787% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 64.294% |
| SYBLEU INC | 330.46 Thousand USD | 58.351% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 66.382% |
| International Stem Cell Corporation | 5.39 Million USD | 97.446% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.083% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.17% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -74.225% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 84.082% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.169% |
| Neutra Corp. | 2851.00 USD | -4727.71% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.575% |
| PureTech Health plc | 693.97 Million USD | 99.98% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.295% |
| IXICO plc | 15.84 Million USD | 99.131% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.338% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.867% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.959% |